Silvia Marfil Verchili
Silvia Marfil has been a clinical analyst since 1992. Following training at the Bonanova Institute of Barcelona, she undertook a work placement at the Hospital de Mar Medical Research Institute (IMIM), after which she was employed by Prodesfarma to work in the immunology departament of the Germans Trias i Pujol University Hospital in Badalona.
More recently she joined IrsiCaixa, where she undertakes tasks in suport of research in the group headed by Dr. Julià Blanco and also works in Albajuna Therapeutics, an IrsiCaixa spin-off. She collaborates with the Xplore Health educational programme, preparing the workshop on investigating the HIV vaccine.
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic.
Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.
Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.